The Avicenna Alliance is the 1 stop shop for all things in silico and health policy at EU level. Industries and research organisations who are impacted by EU policy in these areas should consider membership of the association.
Avicenna Alliance Members
Medtronic is a global healthcare solutions company committed to improving the lives of people through its medical technologies, services, and solutions.
During the six decades of Medtronic’s existence, its Mission has remained the same: to alleviate pain, restore health, and extend life for people around the world. Medtronic has worked hard to be at the forefront of medical device innovation, challenging itself to develop high-quality therapies that positively impact people’s lives.
Medtronic has accomplished a lot — today more than 62 million people benefit from the company’s technologies each year, equating to two people every second. But, Medtronic also knows that it participates in global healthcare systems that are facing intense clinical and economic challenges. If not corrected, these issues may serve to undermine global growth and development and leave millions around the world untreated — for even the simplest diseases. Medtronic believes that what got it to the current state of healthcare is not necessarily what will propel it forward. The future of healthcare requires new approaches and new forms of innovation.
ANSYS' sole focus is engineering simulation. For more than 45 years, it has consistently advanced this technology to meet evolving customer needs.
ANSYS develops, markets and supports engineering simulation software used to predict how product designs will behave in real-world environments. ANSYS continually advances simulation solutions by
- Developing or acquiring the very best technologies
- Integrating them into a unified simulation platform capable of complex, multiphysics solutions
Providing system services, including high-performance computing (HPC) and Cloud solutions, to manage simulation processes and data.
QUIBIM S.L. was created in late 2012 as an initiative from a group of doctors in biomedical engineering and a Key Opinion Leader in radiology with a recognized international scientific career.
QUIBIM is a reference core lab in imaging biomarkers extraction and analysis, born as a spin-off of La Fe Health Research Institute in Valencia (Spain), the renowned research institute of La Fe Polytechnics and University Hospital.
QUIBIM applies advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology.
The company provides state of the art solutions for early diagnosis, lesion grading-phenotyping-staging, treatment selection/follow-up, in addition to the validation against clinical endpoints.
Dompé is a leading Italian biopharmaceutical company focusing on the development of innovative treatment solutions for rare and often orphan diseases in areas with unmet treatment needs, such as diabetes, organ transplants, ophthalmology and oncology. Dompé pursues this objective by promoting and actively participating in a network made up of the best names in each activity of the pharmaceutical industry, from research to development, from production to marketing.
Dompé’s mission is to find innovative solutions to improve human health.
Dompé’s commitment is to transform its efforts in research with passion, skill and courage.
Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring. Driven by a passion to help patients, the company collaborates with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives.
Edwards Lifesciences partner with physicians to innovate products designed to help patients live longer, healthier and more productive lives. The company focuses on medical technologies that address large and growing patient populations in which there are significant unmet clinical needs.
Johnson & Johnson
As a major player in three market segments and with a focus on the full continuum of care – prevention, diagnosis and treatment – Johnson & Johnson competes in fully one-third of the global health care marketplace. Its breadth helps drive consistent performance and enables the company to pursue growth opportunities – including in some of the fastest growing segments of health care – wherever they arise. It allows Johnson & Johnson to respond to purchasing trends with governments and large customers. Perhaps more important, it allows the company to think about patient care holistically, drawing on insights from multiple perspectives in a disease category. In the end, being broadly based allows it to stay true to its Credo in the face of an ever-evolving health care environment.
In silico medicine that works
A pioneer in in silico, NOVADISCOVERY offers a transformative approach to drug R&D based on a reverse engineering methodology combining mathematical models of diseases, drugs and virtual patients which enables the assessment of downstream clinical benefit for patients long before trials on humans.
From a technology standpoint, NOVADISCOVERY has developed a full white box ecosystem, called WISEÆ ("Whitebox In Silico Engine"), to streamline its workflows.
We help our partners de-risk their drug programs by analyzing the impact of critical decisions in terms of clinical benefit, optimize the design of in vitro/in vivo assays and reduce time & costs through a cheaper & faster exploration of key assumptions.
Based in Lyon, France, NOVADISCOVERY brings together a multidisciplinary team of experts dedicated to shifting away from the traditional R&D paradigm, characterized by serendipity and costly trial and error, towards a rational patient outcomes-centric model driven by mathematics and computational sciences.
The Virtual Physiological Human Institute for Integrative Biomedical Research, in short VPH Institute, is an international non-profit organisation incorporated in Belgium, whose mission is to ensure that the Virtual Physiological Human is fully realised, universally adopted, and effectively used both in research and clinic.
Since its establishment the VPH Institute has been collaborating with the community and the European Commission on different initiatives. In particular it contributed to the support action Discipulus, and it is now partners of Avicenna.